Registry series: Hepatocellular carcinoma (2009)

Record number: 
Adverse Occurrence type: 
MPHO Type: 
Estimated frequency: 
Most recent risk assessment (Council of Europe, 2022): Oesophageal, gastric, pancreatic, liver and biliary cancers diagnosed during donor procurement : These tumours are classified as unacceptable risk. Oesophageal, gastric, pancreatic, liver and biliary cancers in the donor history: Treated tumours of these kinds in the donor history are classified as high risk due to their aggressive behaviour. Risk may decrease for early stages after curative therapy, with recurrence-free time > 5 years and with increasing probability of cure, especially in cases of long-term survivors
Time to detection: 
5 months
Alerting signals, symptoms, evidence of occurrence: 
Reported to DTAC 1.5 months posttransplant (not reported which recipient was the first) - no alerting signals published
Demonstration of imputability or root cause: 
DTAC (Disease Transmission Advisory Committee) classifies transmission as proven, no details reported in the paper
Suggest references: